Targeting ganglioneuromas with mTOR inhibitors

Ting Tao; Hui Shi; Adam D Durbin; A Thomas Look

doi:10.1080/23723556.2020.1856621

Targeting ganglioneuromas with mTOR inhibitors

Mol Cell Oncol. 2021 Jan 10;8(1):1856621. doi: 10.1080/23723556.2020.1856621.

Authors

Ting Tao^{1

2}, Hui Shi^{2

3}, Adam D Durbin⁴, A Thomas Look²

Affiliations

¹ Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, China.
² Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
³ College of Animal Sciences, Zhejiang University, Hangzhou, China.
⁴ Division of Molecular Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA.

Abstract

We recently identified activated protein kinase B (PKB/AKT) as a tumorigenic driver in childhood ganglioneuroma. Inhibition of the mechanistic target of rapamycin (mTOR), a serine/threonine kinase downstream of AKT, effectively reduced the tumor burden in zebrafish with ganglioneuroma. We propose a clinical trial of mTOR inhibitors as a means to shrink large ganglioneuromas prior to surgical resection.

Keywords: AKT; Ganglioneuroma; mTOR inhibitor; zebrafish model.

Abstract

Grants and funding